Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 4/2021

01-12-2021 | Obesity

Expected and paradoxical effects of obesity on cancer treatment response

Authors: Marco Gallo, Valerio Adinolfi, Viola Barucca, Natalie Prinzi, Valerio Renzelli, Luigi Barrea, Paola Di Giacinto, Rosaria Maddalena Ruggeri, Franz Sesti, Emanuela Arvat, Roberto Baldelli, Emanuela Arvat, Annamaria Colao, Andrea Isidori, Andrea Lenzi, Roberto Baldell, M. Albertelli, D. Attala, A. Bianchi, A. Di Sarno, T. Feola, G. Mazziotti, A. Nervo, C. Pozza, G. Puliani, P. Razzore, S. Ramponi, S. Ricciardi, L. Rizza, F. Rota, E. Sbardella, M. C. Zatelli, on behalf of the EOLO Group

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2021

Login to get access

Abstract

Obesity, whose prevalence is pandemic and continuing to increase, is a major preventable and modifiable risk factor for diabetes and cardiovascular diseases, as well as for cancer. Furthermore, epidemiological studies have shown that obesity is a negative independent prognostic factor for several oncological outcomes, including overall and cancer-specific survival, for several site-specific cancers as well as for all cancers combined. Yet, a recently growing body of evidence suggests that sometimes overweight and obesity may associate with better outcomes, and that immunotherapy may show improved response among obese patients compared with patients with a normal weight. The so-called ‘obesity paradox’ has been reported in several advanced cancer as well as in other diseases, albeit the mechanisms behind this unexpected relationship are still not clear. Aim of this review is to explore the expected as well as the paradoxical relationship between obesity and cancer prognosis, with a particular emphasis on the effects of cancer therapies in obese people.
Literature
1.
2.
Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6(6):e6–e15.PubMedPubMedCentral
3.
Yang L, Drake BF, Colditz GA. Obesity and other cancers. J Clin Oncol. 2016;34(35):4231–7.PubMed
4.
Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O'Connell MJ, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98(22):1647–54.PubMed
5.
Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and leukemia group B 89803. J Clin Oncol. 2008;26(25):4109–15.PubMedPubMedCentral
6.
Doleman B, Mills KT, Lim S, Zelhart MD, Gagliardi G. Body mass index and colorectal cancer prognosis: a systematic review and meta-analysis. Tech Coloproctol. 2016;20(8):517–35.PubMed
7.
Daniel CR, Shu X, Ye Y, Gu J, Raju GS, Kopetz S, et al. Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer Centre. Br J Cancer. 2016;114(1):103–9.PubMed
8.
Almasaudi AS, et al. The relationship between body mass index and short term postoperative outcomes in patients undergoing potentially curative surgery for colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;121:68–73.PubMed
9.
Majumder K, et al. Premorbid Obesity and Mortality in Patients With Pancreatic Cancer: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2016;14(3):355–368e quiz e32.PubMed
10.
Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627–35.PubMed
11.
Chan DS, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25(10):1901–14.PubMedPubMedCentral
12.
Robinson PJ, Bell RJ, Davis SR. Obesity is associated with a poorer prognosis in women with hormone receptor positive breast cancer. Maturitas. 2014;79(3):279–86.PubMed
13.
Ioannides SJ, Barlow PL, Elwood JM, Porter D. Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review. Breast Cancer Res Treat. 2014;147(2):237–48.PubMed
14.
Jiralerspong S, Goodwin PJ. Obesity and breast Cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol. 2016;34(35):4203–16.PubMed
15.
Chung IY, Lee JW, Lee JS, Park YR, Min YH, Lee Y, et al. Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer. PLoS One. 2017;12(3):e0170311.PubMedPubMedCentral
16.
Sun L, Zhu Y, Qian Q, Tang L. Body mass index and prognosis of breast cancer: an analysis by menstruation status when breast cancer diagnosis. Medicine (Baltimore). 2018;97(26):e11220.
17.
Zhang M, Zhang X, Liu J, Su W, Li J, Zhang S, et al. Body mass index and diabetes are important prognostic signatures for bilateral breast cancer prognosis. J Cell Biochem. 2019;120(5):7363–74.
18.
Purcell SA, Elliott SA, Kroenke CH, Sawyer MB, Prado CM. Impact of body weight and body composition on ovarian Cancer prognosis. Curr Oncol Rep. 2016;18(2):8.PubMed
19.
Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 2009;114(1):121–7.PubMed
20.
Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology. 2006;68(4):741–6.PubMed
21.
Choi Y, Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, et al. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis. Int J Cancer. 2013;132(3):625–34.PubMed
22.
Azvolinsky A. Cancer prognosis: role of BMI and fat tissue. J Natl Cancer Inst. 2014;106(6):dju177.PubMed
23.
Zheng Y, Bao L, Chen J, Pan Y, Wang Q, Chen L, et al. The influence of sex on the prognostic value of body mass index in non-metastasis renal cell carcinoma. Cancer Manag Res. 2019;11:3869–86.PubMedPubMedCentral
24.
Westhoff E, Witjes JA, Fleshner NE, Lerner SP, Shariat SF, Steineck G, et al. Body mass index, diet-related factors, and bladder Cancer prognosis: a systematic review and meta-analysis. Bladder Cancer. 2018;4(1):91–112.PubMedPubMedCentral
25.
Ferro M, Vartolomei MD, Russo GI, Cantiello F, Farhan ARA, Terracciano D, et al. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World J Urol. 2019;37(3):507–14.PubMed
26.
Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008;9(11):1039–47.PubMedPubMedCentral
27.
Abufaraj M, Mari A, Mansy K, Sievert KD. Obesity and its implications on oncological urological surgery. Curr Opin Urol. 2017;27(5):446–55.PubMed
28.
Deneuve S, Tan HK, Eghiaian A, Temam S. Management and outcome of head and neck squamous cell carcinomas in obese patients. Oral Oncol. 2011;47(7):631–5.PubMed
29.
McRackan TR, Watkins JM, Herrin AE, Garrett-Mayer EM, Sharma AK, Day TA, et al. Effect of body mass index on chemoradiation outcomes in head and neck cancer. Laryngoscope. 2008;118(7):1180–5.PubMed
30.
Arthur AE, Peterson KE, Rozek LS, Taylor JM, Light E, Chepeha DB, et al. Pretreatment dietary patterns, weight status, and head and neck squamous cell carcinoma prognosis. Am J Clin Nutr. 2013;97(2):360–8.PubMed
31.
Hollander D, Kampman E, van Herpen CM. Pretreatment body mass index and head and neck cancer outcome: a review of the literature. Crit Rev Oncol Hematol. 2015;96(2):328–38.PubMed
32.
Ferguson MK, et al. Association of body mass index and outcomes after major lung resection. Eur J Cardiothorac Surg. 2014;45(4):e94–9 discussion e99.PubMedPubMedCentral
33.
Gupta A, Majumder K, Arora N, Mayo HG, Singh PP, Beg MS, et al. Premorbid body mass index and mortality in patients with lung cancer: a systematic review and meta-analysis. Lung Cancer. 2016;102:49–59.PubMed
34.
Lam VK, Bentzen SM, Mohindra P, Nichols EM, Bhooshan N, Vyfhuis M, et al. Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2017;104:52–7.PubMed
35.
Zhang X, Liu Y, Shao H, Zheng X. Obesity paradox in lung Cancer prognosis: evolving biological insights and clinical implications. J Thorac Oncol. 2017;12(10):1478–88.PubMed
36.
Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer. 2011;47(11):1606–15.PubMed
37.
Castillo JJ, Reagan JL, Ingham RR, Furman M, Dalia S, Merhi B, et al. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res. 2012;36(7):868–75.PubMed
38.
Breccia M, Mazzarella L, Bagnardi V, Disalvatore D, Loglisci G, Cimino G, et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood. 2012;119(1):49–54.PubMed
39.
Teras LR, Kitahara CM, Birmann BM, Hartge PA, Wang SS, Robien K, et al. Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol. 2014;166(5):667–76.PubMedPubMedCentral
40.
Castillo JJ, Mulkey F, Geyer S, Kolitz JE, Blum W, Powell BL, et al. Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: a pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol. 2016;91(2):199–204.PubMed
41.
Amankwah EK, Saenz AM, Hale GA, Brown PA. Association between body mass index at diagnosis and pediatric leukemia mortality and relapse: a systematic review and meta-analysis. Leuk Lymphoma. 2016;57(5):1140–8.PubMed
42.
Carson KR, Bartlett NL, McDonald JR, Luo S, Zeringue A, Liu J, et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. J Clin Oncol. 2012;30(26):3217–22.PubMedPubMedCentral
43.
Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, et al. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann Oncol. 2014;25(1):171–6.PubMed
44.
Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol. 2013;88(8):642–6.PubMedPubMedCentral
45.
McQuade JL, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018;19(3):310–22.PubMedPubMedCentral
46.
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.PubMed
47.
Batty GD, Shipley MJ, Jarrett RJ, Breeze E, Marmot MG, Smith GD. Obesity and overweight in relation to organ-specific cancer mortality in London (UK): findings from the original Whitehall study. Int J Obes. 2005;29(10):1267–74.
48.
Parekh N, Okada T, Lu-Yao GL. Obesity, insulin resistance, and cancer prognosis: implications for practice for providing care among cancer survivors. J Am Diet Assoc. 2009;109(8):1346–53.PubMedPubMedCentral
49.
Mapp S, Sandhu G, Carrington C, Hennig S. A systematic review of treatment outcomes with weight-based dosing of chemotherapy in obese adult patients with acute leukemia or lymphoma. Leuk Lymphoma. 2016;57(4):981–4.PubMed
50.
Hourdequin KC, Schpero WL, McKenna DR, Piazik BL, Larson RJ. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis. Ann Oncol. 2013;24(12):2952–62.PubMed
51.
Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30(13):1553–61.PubMed
52.
Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer. 2006;13(2):279–92.PubMed
53.
Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. CA Cancer J Clin. 2017;67(5):378–97.PubMedPubMedCentral
54.
Trestini I, Carbognin L, Bonaiuto C, Tortora G, Bria E. The obesity paradox in cancer: clinical insights and perspectives. Eat Weight Disord. 2018;23(2):185–93.PubMed
55.
Murphy WJ, Longo DL. The surprisingly positive association between obesity and Cancer immunotherapy efficacy. JAMA. 2019;321(13):1247–8.PubMed
56.
Chang HH, Eibl G. Obesity-induced adipose tissue inflammation as a strong promotional factor for pancreatic ductal adenocarcinoma. Cell. 2019;8(7):673.
57.
Parikh AM, Coletta AM, Yu ZH, Rauch GM, Cheung JP, Court LE, et al. Development and validation of a rapid and robust method to determine visceral adipose tissue volume using computed tomography images. PLoS One. 2017;12(8):e0183515.PubMedPubMedCentral
58.
Goossens GH. The metabolic phenotype in obesity: fat mass, body fat distribution, and adipose tissue function. Obes Facts. 2017;10(3):207–15.PubMedPubMedCentral
59.
Arcidiacono B, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res. 2012;2012:789174.PubMedPubMedCentral
60.
Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol. 2010;28(26):4058–65.PubMedPubMedCentral
61.
Tsujimoto T, Kajio H, Sugiyama T. Association between hyperinsulinemia and increased risk of cancer death in nonobese and obese people: a population-based observational study. Int J Cancer. 2017;141(1):102–11.PubMedPubMedCentral
62.
Chettouh H, Fartoux L, Aoudjehane L, Wendum D, Clapéron A, Chrétien Y, et al. Mitogenic insulin receptor-a is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors. Cancer Res. 2013;73(13):3974–86.PubMed
63.
Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, McClain DA. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J. 1990;9(8):2409–13.PubMedPubMedCentral
64.
Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7(2):85–96.PubMed
65.
Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014;10(8):455–65.PubMedPubMedCentral
66.
Crowe FL, Key TJ, Allen NE, Appleby PN, Overvad K, Grønbæk H, et al. A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and −3 in the European prospective investigation into Cancer and nutrition (EPIC). Ann Hum Biol. 2011;38(2):194–202.PubMed
67.
Johnson JA, et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012;55(6):1607–18.PubMed
68.
Asano T, Yao Y, Shin S, McCubrey J, Abbruzzese JL, Reddy SAG. Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res. 2005;65(20):9164–8.PubMed
69.
Beauchamp EM, Platanias LC. The evolution of the TOR pathway and its role in cancer. Oncogene. 2013;32(34):3923–32.PubMed
70.
Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol. 2013;15(6):555–64.PubMedPubMedCentral
71.
Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010;466(7308):869–73.PubMed
72.
Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res. 2010;16(9):2505–11.PubMedPubMedCentral
73.
Rozengurt E. Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells. Front Physiol. 2014;5:357.PubMedPubMedCentral
74.
75.
Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40(11):1286–92.PubMed
76.
Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabak AG, Schloot NC, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care. 2009;32(3):421–3.PubMedPubMedCentral
77.
Hirabara SM, et al. Molecular targets related to inflammation and insulin resistance and potential interventions. J Biomed Biotechnol. 2012;2012:379024.PubMedPubMedCentral
78.
Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol. 2000;14(6):783–94.PubMed
79.
Kawasaki N, Asada R, Saito A, Kanemoto S, Imaizumi K. Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue. Sci Rep. 2012;2:799.PubMedPubMedCentral
80.
Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27(13):2217–24.PubMed
81.
Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral actions and interactions. Int J Obes Relat Metab Disord. 2002;26(11):1407–33.PubMed
82.
Tessitore L, Vizio B, Jenkins O, de Stefano I, Ritossa C, Argiles JM, et al. Leptin expression in colorectal and breast cancer patients. Int J Mol Med. 2000;5(4):421–6.PubMed
83.
Divella R, de Luca R, Abbate I, Naglieri E, Daniele A. Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J Cancer. 2016;7(15):2346–59.PubMedPubMedCentral
84.
Booth A, Magnuson A, Fouts J, Foster M. Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Invest. 2015;21(1):57–74.
85.
Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, et al. Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2004;53(9):2473–8.PubMed
86.
Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr. 2007;86(3):s858–66.PubMed
87.
Lu W, et al. Low circulating total adiponectin, especially its non-high-molecular weight fraction, represents a promising risk factor for colorectal cancer: a meta-analysis. Onco Targets Ther. 2018;4(11):2519–31.
88.
Katira A, Tan PH. Evolving role of Adiponectin in Cancer-controversies and update. Cancer Biol Med. 2016;13(1):101–19.PubMedPubMedCentral
89.
Yoon YS, Kwon AR, Lee YK, Oh SW. Circulating Adipokines and risk of obesity related cancers: a systematic review and meta-analysis. Obes Res Clin Pract. 2019;13(4):329–39.PubMed
90.
Shrestha A, Nepal S, Kim MJ, Chang JH, Kim SH, Jeong GS, et al. Critical role of AMPK/FoxO3A Axis in globular Adiponectin-induced cell cycle arrest and apoptosis in Cancer cells. J Cell Physiol. 2016;231(2):357–69.PubMed
91.
Kim K, Kim JK, Han SH, Lim JS, Kim KI, Cho DH, et al. Adiponectin is a negative regulator of NK cell cytotoxicity. J Immunol. 2006;176(10):5958–64.PubMed
92.
Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R, et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab. 2003;88(11):5452–5.PubMed
93.
Dalamaga M, Chou SH, Shields K, Papageorgiou P, Polyzos SA, Mantzoros CS. Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell Metab. 2013;18:29–42.PubMed
94.
Gong WJ, Zheng W, Xiao L, Tan LM, Song J, Li XP, et al. Circulating resistin levels and obesity-related cancer risk: a meta-analysis. Oncotarget. 2016;7:57694–704.PubMedPubMedCentral
95.
Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem. 2008;15(18):1851–562.PubMed
96.
Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178:1748–58.PubMed
97.
Goralski KB, Jackson AE, McKeown BT, Sinal CJ. More than an Adipokine: the complex roles of Chemerin signaling in Cancer. Int J Mol Sci. 2019;20(19):4778.PubMedCentral
98.
Watanabe T, et al. Adipose tissue-derived Omentin-1 function and regulation. Compr Physiol. 2017;7(3):765–81.PubMed
99.
de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56(6):1655–61.PubMed
100.
Kawashima K, Maeda K, Saigo C, Kito Y, Yoshida K, Takeuchi T. Adiponectin and intelectin-1: important adipokine players in obesity-related colorectal carcinogenesis. Int J Mol Sci. 2017;18(4):866.PubMedCentral
101.
Barchetta I, Cimini FA, Ciccarelli G, Baroni MG, Cavallo MG. Sick fat: the good and the bad of old and new circulating markers of adipose tissue inflammation. J Endocrinol Investig. 2019;42(11):1257–72.
102.
Wang B, Wood IS, Trayhurn P. Hypoxia induces leptin gene expression and secretion in human preadipocytes: differential effects of hypoxia on adipokine expression by preadipocytes. J Endocrinol. 2008;198(1):127–34.PubMed
103.
Rogers CJ, Prabhu KS, Vijay-Kumar M. The microbiome and obesity-an established risk for certain types of cancer. Cancer J. 2014;20(3):176–80.PubMed
104.
Keku TO, Dulal S, Deveaux A, Jovov B, Han X. The gastrointestinal microbiota and colorectal cancer. Am J Physiol Gastrointest Liver Physiol. 2015;308(5):G351–63.PubMed
105.
106.
Cani PD, Jordan BF. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2018;15(11):671–82.PubMed
107.
Ohtani N, Yoshimoto S, Hara E. Obesity and cancer: a gut microbial connection. Cancer Res. 2014;74(7):1885–9.PubMed
108.
Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y, et al. Gut microbiota promotes obesity-associated liver Cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discov. 2017;7(5):522–38.PubMed
109.
McQuade JL, Ologun GO, Arora R, Wargo JA. Gut microbiome modulation via fecal microbiota transplant to augment immunotherapy in patients with melanoma or other cancers. Curr Oncol Rep. 2020;22(7):74.PubMedPubMedCentral
110.
Aindelis G, Chlichlia K. Modulation of anti-tumour immune responses by probiotic bacteria. Vaccines (Basel). 2020;8(2):E329.
111.
Dai Z, Zhang J, Wu Q, Fang H, Shi C, Li Z, et al. Intestinal microbiota: a new force in cancer immunotherapy. Cell Commun Signal. 2020;18(1):90.PubMedPubMedCentral
112.
Fong W, Li Q, Yu J. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. Oncogene. 2020;39(26):4925–43.PubMedPubMedCentral
113.
Bhardwaj P, Au CMC, Benito-Martin A, Ladumor H, Oshchepkova S, Moges R, et al. Estrogens and breast cancer: mechanisms involved in obesity-related development, growth and progression. J Steroid Biochem Mol Biol. 2019;189:161–70.PubMedPubMedCentral
114.
Vicennati V, Garelli S, Rinaldi E, Rosetti S, Zavatta G, Pagotto U, et al. Obesity-related proliferative diseases: the interaction between adipose tissue and estrogens in post-menopausal women. Horm Mol Biol Clin Invest. 2015;21(1):75–87.
115.
Gerard C, Brown KA. Obesity and breast cancer - role of estrogens and the molecular underpinnings of aromatase regulation in breast adipose tissue. Mol Cell Endocrinol. 2018;466:15–30.PubMed
116.
Wang X, Simpson ER, Brown KA. Aromatase overexpression in dysfunctional adipose tissue links obesity to postmenopausal breast cancer. J Steroid Biochem Mol Biol. 2015;153:35–44.PubMed
117.
Gucalp A, Iyengar NM, Hudis CA, Dannenberg AJ. Targeting obesity-related adipose tissue dysfunction to prevent cancer development and progression. Semin Oncol. 2016;43(1):154–60.PubMed
118.
Zahid H, Simpson ER, Brown KA. Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer. Curr Opin Pharmacol. 2016;31:90–6.PubMed
119.
Frei E 3rd. And G.P. Canellos, Dose: a critical factor in cancer chemotherapy. Am J Med. 1980;69(4):585–94.PubMed
120.
Lyman GH, Sparreboom A. Chemotherapy dosing in overweight and obese patients with cancer. Nat Rev Clin Oncol. 2013;10(8):451–9.PubMed
121.
Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165(11):1267–73.PubMed
122.
Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, et al. Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008;26(25):4072–7.PubMedPubMedCentral
123.
Del Fabbro E, et al. The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012;17(10):1240–5.PubMedPubMedCentral
124.
Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013;119(8):1528–36.PubMed
125.
Sepesi B, Gold KA, Correa AM, Heymach JV, Vaporciyan AA, Roszik J, et al. The influence of body mass index on overall survival following surgical resection of non-small cell lung Cancer. J Thorac Oncol. 2017;12(8):1280–7.PubMedPubMedCentral
126.
Abdel-Rahman O. Effect of body mass index on 5-FU-based chemotherapy toxicity and efficacy among patients with metastatic colorectal Cancer; a pooled analysis of 5 randomized trials. Clin Colorectal Cancer. 2019;18:110–115.e2.PubMed
127.
Ewertz M, Jensen MB, Gunnarsdóttir KÁ, Højris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2011;29(1):25–31.PubMed
128.
Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20(4):1128–43.PubMed
129.
Poortman J, Thijssen JH, de Waard F. Plasma oestrone, oestradiol and androstenedione levels in post-menopausal women: relation to body weight and height. Maturitas. 1981;3(1):65–71.PubMed
130.
Goodwin PJ, Pritchard KI. Obesity and hormone therapy in breast cancer: an unfinished puzzle. J Clin Oncol. 2010;28(21):3405–7.PubMed
131.
Cleary MP, Grossmann ME. Minireview: obesity and breast cancer: the estrogen connection. Endocrinology. 2009;150(6):2537–42.PubMedPubMedCentral
132.
Renehan AG, Roberts DL, Dive C. Obesity and cancer: pathophysiological and biological mechanisms. Arch Physiol Biochem. 2008;114(1):71–83.PubMed
133.
Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28(21):3411–5.PubMed
134.
Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thürlimann B, et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol. 2012;30(32):3967–75.PubMedPubMedCentral
135.
Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29(19):2653–9.PubMed
136.
Artac M, et al. Bevacuzimab may be less effective in obese metastatic colorectal Cancer patients. J Gastrointest Cancer. 2019;50(2):214–20.PubMed
137.
Hopirtean C, Ciuleanu T, Cainap C, Todor N, Nagy V. Body mass index as a prognostic factor for disease progression in patients with metastatic colorectal Cancer treated with Bevacizumab based systemic therapy. Acta Endocrinol (Buchar). 2017;13(4):425–30.
138.
Faruk Aykan N, Yildiz I, Sen F, Kilic L, Keskin S, Ciftci R, et al. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy. Med Oncol. 2013;30(3):679.PubMedPubMedCentral
139.
Simkens LH, et al. Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. Eur J Cancer. 2011;47(17):2560–7.PubMed
140.
Patel GS, Ullah S, Beeke C, Hakendorf P, Padbury R, Price TJ, et al. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. Cancer Med. 2015;4(10):1461–71.PubMedPubMedCentral
141.
Kaidar-Person O, Badarna H, Bar-Sela G. Bevacizumab for metastatic colon cancer: does patient BMI influence survival? Anti-Cancer Drugs. 2015;26(3):363–6.PubMed
142.
Zafar Y, et al. LBA-01Survival outcomes according to body mass index (BMI): results from a pooled analysis of 5 observational or phase IV studies of bevacizumab in metastatic colorectal cancer (mCRC). Ann Oncol. 2015;26(suppl_4):iv117–7.
143.
Miyamoto Y, Oki E, Emi Y, Tokunaga S, Shimokawa M, Ogata Y, et al. Low visceral fat content is a negative predictive marker for Bevacizumab in metastatic colorectal Cancer. Anticancer Res. 2018;38(1):491–9.PubMed
144.
Slaughter KN, Thai T, Penaroza S, Benbrook DM, Thavathiru E, Ding K, et al. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol. 2014;133(1):11–5.PubMed
145.
Pizzuti L, Sergi D, Sperduti I, Lauro LD, Mazzotta M, Botti C, et al. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. Cancer Biol Ther. 2018;19(4):328–34.PubMedPubMedCentral
146.
Steffens S, Grünwald V, Ringe KI, Seidel C, Eggers H, Schrader M, et al. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist. 2011;16(11):1565–71.PubMedPubMedCentral
147.
Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J Clin Oncol. 2016;34(30):3655–63.PubMedPubMedCentral
148.
Song Y, et al. Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Urol Oncol. 2016;34(6):258 e15–22.
149.
Mizuno R, Miyajima A, Hibi T, Masuda A, Shinojima T, Kikuchi E, et al. Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy. Med Oncol. 2017;34(4):47.PubMed
150.
Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013;108(5):1034–41.PubMedPubMedCentral
151.
Antoun S, et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21(8):1594–8.PubMed
152.
Labenz C, Prenosil V, Koch S, Huber Y, Marquardt JU, Schattenberg JM, et al. Impact of individual components of the metabolic syndrome on the outcome of patients with advanced hepatocellular carcinoma treated with Sorafenib. Dig Dis. 2018;36(1):78–88.PubMed
153.
Martel S, Poletto E, Ferreira AR, Lambertini M, Sottotetti F, Bertolini I, et al. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer. Breast. 2018;37:142–7.PubMed
154.
Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer. 2013;119(13):2447–54.PubMed
155.
Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, et al. Obesity as a risk factor for Anthracyclines and Trastuzumab Cardiotoxicity in breast Cancer: a systematic review and meta-analysis. J Clin Oncol. 2016;34(26):3157–65.PubMedPubMedCentral
156.
Cheraghi Z, Ayubi E, Doosti-Irani A. Obesity as a risk factor for Anthracyclines and Trastuzumab Cardiotoxicity in breast Cancer: Methodologic issues to avoid misinterpretation in the meta-analysis. J Clin Oncol. 2017;35(8):923.PubMed
157.
Wang HY, Yin BB, Jia DY, Hou YL. Association between obesity and trastuzumab-related cardiac toxicity in elderly patients with breast cancer. Oncotarget. 2017;8(45):79289–97.PubMedPubMedCentral
158.
Kosalka P, Johnson C, Turek M, Sulpher J, Law A, Botros J, et al. Effect of obesity, dyslipidemia, and diabetes on trastuzumab-related cardiotoxicity in breast cancer. Curr Oncol. 2019;26(3):e314–21.PubMedPubMedCentral
159.
Chen CT, du Y, Yamaguchi H, Hsu JM, Kuo HP, Hortobagyi GN, et al. Targeting the IKKbeta/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Mol Cancer Ther. 2012;11(10):2212–21.PubMedPubMedCentral
160.
Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, et al. Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: the EverExt study. Sci Rep. 2017;7(1):10597.PubMedPubMedCentral
161.
Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, et al. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Investig New Drugs. 2019;37(2):345–51.
162.
Park S, Park S, Lee SH, Suh B, Keam B, Kim TM, et al. Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. Korean J Intern Med. 2016;31(6):1140–9.PubMedPubMedCentral
163.
Boker B, Luders H, Grohe C. Prognostic relevance of body mass index and rash for patients with metastatic non-small-cell lung cancer under therapy with erlotinib. Pneumologie. 2012;66(2):89–95.PubMed
164.
Rossi S, di Noia V, Tonetti L, Strippoli A, Basso M, Schinzari G, et al. Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations? Future Oncol. 2018;14(10):919–26.PubMed
165.
Imai H, Kuwako T, Kaira K, Masuda T, Miura Y, Seki K, et al. Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2017;79(3):497–505.PubMedPubMedCentral
166.
Sun H, Sun X, Zhai X, Guo J, Liu Y, Ying J, et al. Body mass index and exon 19 mutation as factors predicting the therapeutic efficacy of gefitinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer. Thorac Cancer. 2016;7(1):61–5.PubMed
167.
Kudo K, Hotta K, Ichihara E, Yoshioka H, Kunimasa K, Tsubouchi K, et al. Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama lung Cancer study group 0703. Cancer Chemother Pharmacol. 2015;76(2):251–6.PubMed
168.
Ichihara E, Hotta K, Takigawa N, Kudo K, Kato Y, Honda Y, et al. Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations. Lung Cancer. 2013;81(3):435–9.PubMed
169.
Oda N, Hotta K, Yoshioka H, Kudo K, Ichihara E, Kato Y, et al. Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama lung Cancer study group experience. Cancer Chemother Pharmacol. 2016;78(5):941–7.PubMed
170.
Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17(12):e542–51.PubMedPubMedCentral
171.
Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177–85.PubMed
172.
Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, le CT, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25(1):141–51.PubMed
173.
Naik GS, Waikar SS, Johnson AEW, Buchbinder EI, Haq R, Hodi FS, et al. Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. J Immunother Cancer. 2019;7(1):89.PubMedPubMedCentral
174.
Richtig G, Hoeller C, Wolf M, Wolf I, Rainer BM, Schulter G, et al. Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-Centre study. PLoS One. 2018;13(10):e0204729.PubMedPubMedCentral
175.
Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer. 2019;7(1):57.PubMedPubMedCentral
Metadata
Title
Expected and paradoxical effects of obesity on cancer treatment response
Authors
Marco Gallo
Valerio Adinolfi
Viola Barucca
Natalie Prinzi
Valerio Renzelli
Luigi Barrea
Paola Di Giacinto
Rosaria Maddalena Ruggeri
Franz Sesti
Emanuela Arvat
Roberto Baldelli
Emanuela Arvat
Annamaria Colao
Andrea Isidori
Andrea Lenzi
Roberto Baldell
M. Albertelli
D. Attala
A. Bianchi
A. Di Sarno
T. Feola
G. Mazziotti
A. Nervo
C. Pozza
G. Puliani
P. Razzore
S. Ramponi
S. Ricciardi
L. Rizza
F. Rota
E. Sbardella
M. C. Zatelli
on behalf of the EOLO Group
Publication date
01-12-2021
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 4/2021
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-020-09597-y

Other articles of this Issue 4/2021

Reviews in Endocrine and Metabolic Disorders 4/2021 Go to the issue

ReviewPaper

Role of vitamin D in diabetic retinopathy: Pathophysiological and clinical aspects

ReviewPaper

Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes

ReviewPaper

Is constitutional thinness really different from anorexia nervosa? A systematic review and meta-analysis

Unsolicited Review

Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review

ReviewPaper

Paediatric Cushing’s disease: Epidemiology, pathogenesis, clinical management and outcome

ReviewPaper

Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits